From GlobeNewswire: 2025-06-16 18:40:00

Enzo Biochem, Inc. reported a decline in third-quarter revenue to $6.4 million, a 20% decrease from the prior year. The company launched 100 new products during the quarter in an effort to drive new revenues. Despite a decrease in revenue, operating loss for the nine months of FY25 decreased by $1.1 million due to cost containment initiatives. Enzo ended the quarter with $36.7 million in cash and cash equivalents and working capital of $31.3 million. The company reached a class-wide settlement agreement related to a cyber incident and is exploring strategic alternatives, including a potential transaction. Enzo voluntarily delisted its common stock from NYSE and began trading on OTCQX.

Enzo Biochem, Inc. operates as a life sciences company and focuses on labeling and detection technologies. The company’s primary business is conducted through its Life Sciences division, Enzo Life Sciences, offering thousands of high-quality products for research and drug development. Enzo utilizes a global distribution network for sales and licensing. The company’s non-GAAP financial measures include Adjusted net loss, EBITDA, and Adjusted EBITDA for supplemental analysis. The reconciliation of these measures is available on the company’s website. Selected balance sheet data as of April 30, 2025, shows cash and cash equivalents of $36,693 and working capital of $31,267. For the three months ended April 30, 2025, the company reported a GAAP net loss of ($2,790) and Adjusted net loss of ($2,106). EBITDA was ($2,856) and Adjusted EBITDA was ($2,680).



Read more at GlobeNewswire: Enzo Biochem Reports Third Quarter Fiscal Year 2025